X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (67) 67
oncology (59) 59
index medicus (54) 54
female (53) 53
aged (45) 45
male (45) 45
chemotherapy (40) 40
lung neoplasms - drug therapy (40) 40
middle aged (39) 39
carcinoma, non-small-cell lung - drug therapy (34) 34
adult (29) 29
lung cancer (28) 28
treatment outcome (26) 26
lung neoplasms - genetics (25) 25
carcinoma, non-small-cell lung - genetics (23) 23
aged, 80 and over (22) 22
gefitinib (22) 22
antineoplastic agents - therapeutic use (20) 20
disease-free survival (20) 20
lung cancer, non-small cell (20) 20
mutation (19) 19
erlotinib (18) 18
lung neoplasms - pathology (18) 18
animals (17) 17
receptor, epidermal growth factor - genetics (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
cancer (16) 16
japan (16) 16
respiratory system (16) 16
care and treatment (15) 15
lung neoplasms - mortality (15) 15
mice (14) 14
neoplasm staging (14) 14
non-small cell lung cancer (14) 14
carboplatin - administration & dosage (13) 13
quinazolines - therapeutic use (13) 13
trial (13) 13
antineoplastic agents - adverse effects (12) 12
carcinoma, non-small-cell lung - mortality (12) 12
carcinoma, non-small-cell lung - pathology (12) 12
hematology, oncology and palliative medicine (12) 12
research (12) 12
adenocarcinoma (11) 11
analysis (11) 11
cancer therapies (11) 11
clinical trials (11) 11
pulmonary/respiratory (10) 10
survival rate (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
carboplatin (9) 9
hepatocyte growth factor - genetics (9) 9
medicine & public health (9) 9
multicenter (9) 9
open-label (9) 9
prognosis (9) 9
prospective studies (9) 9
protein kinase inhibitors - therapeutic use (9) 9
1st-line treatment (8) 8
adenocarcinoma - genetics (8) 8
adenoviridae - genetics (8) 8
cancer research (8) 8
egfr (8) 8
genetic vectors (8) 8
growth-factor receptor (8) 8
mice, inbred balb c (8) 8
nsclc (8) 8
oncology, experimental (8) 8
studies (8) 8
therapy (8) 8
tumors (8) 8
adenocarcinoma - drug therapy (7) 7
apoptosis (7) 7
combination (7) 7
follow-up studies (7) 7
medicine, research & experimental (7) 7
mutation - genetics (7) 7
non-small cell lung carcinoma (7) 7
patients (7) 7
respiratory tract diseases (7) 7
survival analysis (7) 7
4-kringle antagonist (6) 6
amrubicin (6) 6
antineoplastic agents - administration & dosage (6) 6
biotechnology & applied microbiology (6) 6
cell line, tumor (6) 6
cell lung-cancer (6) 6
cisplatin (6) 6
disease progression (6) 6
docetaxel (6) 6
drug administration schedule (6) 6
expression (6) 6
genetic aspects (6) 6
genetics & heredity (6) 6
hepatocyte growth-factor (6) 6
medical research (6) 6
mice, nude (6) 6
nivolumab (6) 6
paclitaxel (6) 6
paclitaxel - administration & dosage (6) 6
receptor, epidermal growth factor - antagonists & inhibitors (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Oncology, ISSN 1470-2045, 07/2019, Volume 20, Issue 7, pp. e345 - e345
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 541 - 543
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | GEFITINIB | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell | Index Medicus
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1000 - 1006
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and Alvarez Alvarez, Rosa and Yang, Chih-Hsin and Hsia, Te-Chun and Denis, Fabrice and Sakai, Hiroshi and Vincent, Mark and Goto, Koichi and Bosch-Barrera, Joaquim and Weiss, Glen and Canon, Jean-Luc and Scholz, Christian and Aglietta, Massimo and Kemmotsu, Hirotsugu and Azuma, Koichi and Bradbury, Penelope and Feld, Ronald and Chachoua, Abraham and Jassem, Jacek and Juergens, Rosalyn and Palmero Sanchez, Ramon and Malcolm, Albert and Vrindavanam, Nandagopal and Kubota, Kaoru and Waller, Cornelius and Waterhouse, David and Coudert, Bruno and Mark, Zsuzsanna and ... and ATLANTIC Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 521 - 536
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without tyrosine kinase or anaplastic... 
MULTICENTER | METAANALYSIS | NSCLC | ONCOLOGY | RANDOMIZED CONTROLLED-TRIAL | ATEZOLIZUMAB | IMMUNE CHECKPOINT | NIVOLUMAB | MEDI4736 | CLINICAL ACTIVITY | DOCETAXEL | Lung cancer, Non-small cell | Care and treatment
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 2/2017, Volume 22, Issue 1, pp. 70 - 78
In Japan, the clinical efficacy of erlotinib monotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was... 
EGFR mutations | Medicine & Public Health | Erlotinib | Non-small-cell lung cancer (NSCLC) | First line | Oncology | Cancer Research | Japanese patients | Overall survival | Surgical Oncology | GEFITINIB | NSCLC | CHEMOTHERAPY | TYROSINE KINASE INHIBITORS | IMPACT | THERAPY | CISPLATIN | ONCOLOGY | BRAIN METASTASES | AFATINIB | PROGRESSION | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Aged, 80 and over | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Erlotinib Hydrochloride - administration & dosage | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Research Design | Epidermal growth factor | Gene mutations | Analysis | Oncology, Experimental | Patient outcomes | Research | Lung cancer, Non-small cell | Cancer | Original
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2010, Volume 362, Issue 25, pp. 2380 - 2388
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2017, Volume 35, Issue 2, pp. 217 - 226
Objectives To determine the recommended dose and efficacy/safety of docetaxel combined with resminostat (DR) in non-small cell lung cancer (NSCLC) patients... 
Histone deacetylase inhibitor | Medicine & Public Health | Randomized phase II | Non-small cell lung cancer | Docetaxel | Oncology | Pharmacology/Toxicology | Resminostat | MULTICENTER | PLACEBO | ROMIDEPSIN | TRIAL | ONCOLOGY | DOUBLE-BLIND | LYMPHOMA | PHARMACOLOGY & PHARMACY | JAPANESE PATIENTS | NIVOLUMAB | EXPRESSION | ERLOTINIB | Lung Neoplasms - drug therapy | Humans | Hydroxamic Acids - adverse effects | Lung Neoplasms - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Platinum Compounds - therapeutic use | Histone Deacetylase Inhibitors - pharmacokinetics | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - metabolism | Treatment Outcome | Sulfonamides - pharmacokinetics | Hydroxamic Acids - pharmacokinetics | Taxoids - pharmacokinetics | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Hydroxamic Acids - therapeutic use | Aged | Histone Deacetylase Inhibitors - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Histone Deacetylase Inhibitors - adverse effects | Chemotherapy | Usage | Care and treatment | Safety and security measures | Dosage and administration | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article